Vanessa Barth, PhD is Senior Advisor, External Innovation New Therapeutic Modalities for Eli Lilly and Co. Dr. Barth brings 18 years of industrial experience with a strong emphasis in cross-functional collaboration in both scientific and operational arenas. Most recently, Dr. Barth served as Senior Director at Eli Lilly and Company in Lilly Research Laboratories responsible for Strategic Completive Intelligence & Scientific Support. In this role, Dr. Barth built a diverse, inclusive team of competitive intelligence professionals tasked with bringing an objective and external perspective to strategy and decision-making associated with therapeutic and functional business areas in support of the research portfolio. Vanessa also led the reshaping of Lilly Research Laboratories outsourcing resulting in increased efficiency.
Prior to moving in to operations, Dr. Barth led the tracer discovery and receptor occupancy efforts for Lilly Research Laboratories. In this capacity, Vanessa transformed the manner in which many global outfits approach radiotracer discovery through the unique application of a well-established technology, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Success in identifying novel tracers led Dr. Barth to engage a global network of imaging centers to collaborate on clinical translation of novel tracers to ensure target engagement and enable Phase 2 dose selection as captured in her publications.
Vanessa received her Bachelor of Arts degree in neuroscience from Pomona College, The Claremont Colleges and her Ph.D. in medical neurobiology from Indiana University. Dr. Barth has extensive experience in pharmaceutical research and development, research collaborations, and outsourcing management.
Prior to moving in to operations, Dr. Barth led the tracer discovery and receptor occupancy efforts for Lilly Research Laboratories. In this capacity, Vanessa transformed the manner in which many global outfits approach radiotracer discovery through the unique application of a well-established technology, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Success in identifying novel tracers led Dr. Barth to engage a global network of imaging centers to collaborate on clinical translation of novel tracers to ensure target engagement and enable Phase 2 dose selection as captured in her publications.
Vanessa received her Bachelor of Arts degree in neuroscience from Pomona College, The Claremont Colleges and her Ph.D. in medical neurobiology from Indiana University. Dr. Barth has extensive experience in pharmaceutical research and development, research collaborations, and outsourcing management.
Speaking In
3:00 PM - 4:00 PM
Wednesday, June 7
